Virginia lawmakers are moving on a bill that tightens rules for compounding pharmacies, and the change could reach further than most people expect. If you rely on compounded semaglutide because the brand-name version is too expensive or hard to find, this is worth watching closely. The bill does not target GLP-1 drugs by name, but its new restrictions on compounding practices could limit what pharmacies in Virginia are allowed to prepare and sell.
Virginia HB 917 focuses on how compounding pharmacies handle bulk drug substances and recordkeeping, and those requirements are the mechanism that could squeeze compounded semaglutide out of the market. Compounded versions of GLP-1 medications exist because pharmacies can mix the active ingredient in bulk form, often at a lower cost than the brand-name injectable. If the bill adds new restrictions on how pharmacies source or document those bulk substances, some pharmacies may decide the compliance burden is not worth it and stop offering compounded semaglutide altogether. For patients who have been using a compounded version to manage cost, this means the option could simply disappear, even if the drug itself was never the target of the legislation. The bill has not passed yet, so the outcome is not settled, but the direction it is heading in should not be ignored by anyone currently filling a compounded prescription in Virginia.
If you live in Virginia and currently fill a compounded semaglutide prescription, it may be worth a conversation with your prescriber now about backup options, rather than waiting until a pharmacy tells you the product is no longer available. You can also check with your pharmacy directly to see whether they expect this bill to affect their compounding practices. Keep an eye on the bill's progress through the legislature, since amendments could change its scope before a final vote. Acting early gives you more room to adjust if the rules do shift.
Key details
Virginia patients using compounded semaglutide may need to find another option if this…
Read this on GLP1Laws: https://glp1laws.com/patient-lens/access-roundup-2026-07-20